topamax
janssen-cilag pty ltd - topiramate -
topamax sprinkle
janssen-cilag pty ltd - topiramate -
topamax
janssen-cilag (new zealand) ltd - topiramate 100mg; ; - film coated tablet - 100 mg - active: topiramate 100mg excipient: carnauba wax lactose monohydrate magnesium stearate microcrystalline cellulose opadry yellow ys-1-6370-g sodium starch glycolate starch - topamax is indicated in adults and children, 2 years and over: · as monotherapy in patients with newly diagnosed epilepsy · for conversion to monotherapy in patients with epilepsy · as add-on therapy in partial onset seizures, generalised tonic-clonic seizures or seizures associated with lennox-gastaut syndrome.
topamax
janssen-cilag (new zealand) ltd - topiramate 200mg; ; - film coated tablet - 200 mg - active: topiramate 200mg excipient: carnauba wax lactose monohydrate magnesium stearate microcrystalline cellulose opadry pink ys-1-1456-g as opadry pink ys-1-1759-g sodium starch glycolate starch - topamax is indicated in adults and children, 2 years and over: · as monotherapy in patients with newly diagnosed epilepsy · for conversion to monotherapy in patients with epilepsy · as add-on therapy in partial onset seizures, generalised tonic-clonic seizures or seizures associated with lennox-gastaut syndrome.
topamax
janssen-cilag (new zealand) ltd - topiramate 25mg; - film coated tablet - 25 mg - active: topiramate 25mg excipient: carnauba wax lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-7706-g sodium starch glycolate starch - topamax is indicated in adults and children, 2 years and over: · as monotherapy in patients with newly diagnosed epilepsy · for conversion to monotherapy in patients with epilepsy · as add-on therapy in partial onset seizures, generalised tonic-clonic seizures or seizures associated with lennox-gastaut syndrome.
topamax
janssen-cilag (new zealand) ltd - topiramate 300mg; - film coated tablet - 300 mg - active: topiramate 300mg excipient: carnauba wax lactose monohydrate magnesium stearate microcrystalline cellulose opadry as opadry red ys-1-1759-g sodium starch glycolate starch
topamax
janssen-cilag (new zealand) ltd - topiramate 50mg; ; - film coated tablet - 50 mg - active: topiramate 50mg excipient: carnauba wax lactose monohydrate magnesium stearate microcrystalline cellulose opadry yellow ys-1-6370-g sodium starch glycolate starch - topamax is indicated in adults and children, 2 years and over: · as monotherapy in patients with newly diagnosed epilepsy · for conversion to monotherapy in patients with epilepsy · as add-on therapy in partial onset seizures, generalised tonic-clonic seizures or seizures associated with lennox-gastaut syndrome.
topamax sprinkle
janssen-cilag (new zealand) ltd - topiramate 15mg; ; - capsule - 15 mg - active: topiramate 15mg excipient: cellulose acetate gelatin opacode black s-1-17822 opacode black s-1-17823 povidone sucrose - topamax is indicated in adults and children, 2 years and over: · as monotherapy in patients with newly diagnosed epilepsy · for conversion to monotherapy in patients with epilepsy · as add-on therapy in partial onset seizures, generalised tonic-clonic seizures or seizures associated with lennox-gastaut syndrome.
topamax sprinkle
janssen-cilag (new zealand) ltd - topiramate 25mg; ; - capsule - 25 mg - active: topiramate 25mg excipient: cellulose acetate gelatin opacode black s-1-17822 opacode black s-1-17823 povidone sucrose - topamax is indicated in adults and children, 2 years and over: · as monotherapy in patients with newly diagnosed epilepsy · for conversion to monotherapy in patients with epilepsy · as add-on therapy in partial onset seizures, generalised tonic-clonic seizures or seizures associated with lennox-gastaut syndrome.
topamax sprinkle
janssen-cilag (new zealand) ltd - topiramate 50mg; ; - capsule - 50 mg - active: topiramate 50mg excipient: cellulose acetate gelatin opacode black s-1-17822 opacode black s-1-17823 povidone sucrose - topamax is indicated in adults and children, 2 years and over: · as monotherapy in patients with newly diagnosed epilepsy · for conversion to monotherapy in patients with epilepsy · as add-on therapy in partial onset seizures, generalised tonic-clonic seizures or seizures associated with lennox-gastaut syndrome.